יחס שווי פעילות לרווח לפני ריבית, מסים ופחת: Checkpoint Therapeutics (CKPT)

Checkpoint Therapeutics (CKPT) develops anti-tumor antibodies, leveraging the capacities of Western contract manufacturing organizations to reduce costs. However, military conflicts and sanctions are hindering biomaterial logistics and international trials. This chart reflects an EV/EBITDA multiple of , while patent protection has been weakened by pressure from pharma behemoths and FDA requirements, limiting the business's market advantage.

For the biotechnology sector, EV/EBITDA serves as a key measure of business value, accounting for net debt relative to operating profit. The dynamic EV/EBITDA ratio of a company demonstrates how many years are required for asset payback at the current yield level. For Checkpoint Therapeutics (CKPT), this metric reflects market expectations for the commercialization of oncology drugs through the search for a strategic partner, determining the stability of the capital structure.